[go: up one dir, main page]

MX2023006366A - Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. - Google Patents

Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.

Info

Publication number
MX2023006366A
MX2023006366A MX2023006366A MX2023006366A MX2023006366A MX 2023006366 A MX2023006366 A MX 2023006366A MX 2023006366 A MX2023006366 A MX 2023006366A MX 2023006366 A MX2023006366 A MX 2023006366A MX 2023006366 A MX2023006366 A MX 2023006366A
Authority
MX
Mexico
Prior art keywords
extended release
dosing regimens
injectable formulations
regimens associated
release paliperidone
Prior art date
Application number
MX2023006366A
Other languages
English (en)
Inventor
Srihari Gopal
Raja Venkatasubramanian
Huybrecht T''jollyn
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75888043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023006366(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2023006366A publication Critical patent/MX2023006366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método para tratar pacientes con formulaciones de palmitato de paliperidona inyectable de acción prolongada.
MX2023006366A 2020-11-30 2021-05-07 Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. MX2023006366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063119405P 2020-11-30 2020-11-30
PCT/EP2021/062147 WO2022111859A1 (en) 2020-11-30 2021-05-07 Dosing regimens associated with extended release paliperidone injectable formulations

Publications (1)

Publication Number Publication Date
MX2023006366A true MX2023006366A (es) 2023-08-07

Family

ID=75888043

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023006366A MX2023006366A (es) 2020-11-30 2021-05-07 Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2024009188A MX2024009188A (es) 2020-11-30 2023-05-30 Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024009188A MX2024009188A (es) 2020-11-30 2023-05-30 Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.

Country Status (22)

Country Link
US (2) US11304951B1 (es)
EP (2) EP4025188B1 (es)
JP (1) JP2023552329A (es)
KR (2) KR20250053980A (es)
CN (1) CN116583270A (es)
AU (2) AU2021386450B2 (es)
CA (1) CA3203566A1 (es)
DK (1) DK4025188T3 (es)
ES (1) ES2973583T3 (es)
FI (1) FI4025188T3 (es)
HR (1) HRP20240074T1 (es)
HU (1) HUE065573T2 (es)
IL (1) IL303253A (es)
LT (1) LT4025188T (es)
MX (2) MX2023006366A (es)
PL (1) PL4025188T3 (es)
PT (1) PT4025188T (es)
RS (1) RS65178B1 (es)
SI (1) SI4025188T1 (es)
SM (1) SMT202400077T1 (es)
TW (1) TWI877363B (es)
WO (1) WO2022111859A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021386450B2 (en) * 2020-11-30 2024-03-21 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
SMT202400075T1 (it) 2020-11-30 2024-03-13 Janssen Pharmaceutica Nv Regimi di dosaggio associati con formulazioni iniettabili di paliperidone a rilascio prolungato
MX2023006369A (es) 2020-11-30 2023-08-09 Janssen Pharmaceutica Nv Metodos para asegurar resuspension de formulaciones de palmitato de paliperidona.
JP2023551009A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ．ベー． 持続放出パリペリドン注射可能製剤に関連する投与レジメン
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US20080214808A1 (en) 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
HUE053904T2 (hu) * 2007-12-19 2021-07-28 Janssen Pharmaceutica Nv Hosszan tartó hatású injektálható paliperidon-észterekkel kapcsolatos adagolási rendek
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
AU2010313290A1 (en) 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
PL2529757T3 (pl) 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon
WO2016157061A1 (en) 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
WO2016164218A1 (en) * 2015-04-07 2016-10-13 Janssen Pharmaceuticals, Inc. Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK1254640A1 (zh) * 2015-06-19 2019-07-26 Janssen Pharmaceutica, N.V. 用於药物施用和混合的设备和方法及用於所述设备和方法的适当技术的训练
ES3037855T3 (en) 2017-12-14 2025-10-08 SpecGx LLC One step milling process for preparing micronized paliperidone esters
AU2021386450B2 (en) * 2020-11-30 2024-03-21 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Also Published As

Publication number Publication date
SMT202400077T1 (it) 2024-03-13
PT4025188T (pt) 2024-02-29
KR102794804B1 (ko) 2025-04-10
EP4356966A2 (en) 2024-04-24
AU2024204213A1 (en) 2024-07-11
TW202222319A (zh) 2022-06-16
JP2023552329A (ja) 2023-12-15
ES2973583T3 (es) 2024-06-20
DK4025188T3 (da) 2024-03-04
HUE065573T2 (hu) 2024-06-28
AU2021386450A9 (en) 2025-03-13
HRP20240074T1 (hr) 2024-03-29
CA3203566A1 (en) 2022-06-02
CN116583270A (zh) 2023-08-11
EP4025188B1 (en) 2024-01-10
KR20250053980A (ko) 2025-04-22
US11304951B1 (en) 2022-04-19
FI4025188T3 (fi) 2024-02-21
MX2024009188A (es) 2024-08-06
LT4025188T (lt) 2024-03-12
TWI877363B (zh) 2025-03-21
PL4025188T3 (pl) 2024-06-17
RS65178B1 (sr) 2024-03-29
EP4356966A3 (en) 2024-07-17
IL303253A (en) 2023-07-01
US20220249495A1 (en) 2022-08-11
KR20230116013A (ko) 2023-08-03
WO2022111859A1 (en) 2022-06-02
AU2021386450A1 (en) 2023-07-13
AU2021386450B2 (en) 2024-03-21
SI4025188T1 (sl) 2024-03-29
EP4025188A1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
ZA202400851B (en) Dosing regimens associated with extended release paliperidone injectable formulations
MX2024009188A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2023006368A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
CL2019001292A1 (es) Nuevos derivados de quinolina.
CL2020000301A1 (es) Nuevos derivados de quinolina.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
CO6300949A2 (es) Regimen de dosificacion asociado con esteres de paliperidona inyectables de accion prolongada
WO2019099639A8 (en) Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
MX378969B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
BR112017000470A2 (pt) composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
MX376312B (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
EA201992612A1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
CL2021000529A1 (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
MX2019001860A (es) Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2019011847A (es) Metodo para tratar un efecto secundario de la terapia de celulas t con receptor de antigeno quimerico (car).